Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma
This trial is active, not recruiting.
|Collaborator||Centre Hospitalier Universitaire, Amiens|
|Start date||September 2013|
|End date||June 2017|
|Trial size||45 participants|
|Trial identifier||NCT01956695, 2012-003786-17, IC 2012-05|
Because Primary Central Nervous System Lymphoma (PCNSL) are mainly diffuse large B-cell lymphoma of the activated B cells (ABC) type, the investigators hypothesize that the synergy of lenalidomide with rituximab shown in systemic non-Hodgkin's lymphoma (NHL) could be observed in PCNSL.
This study will assess the efficiency of the the combination of lenalidomide and rituximab in relapsed/refractory PCNSL, and the efficiency of a maintenance treatment with lenalidomide alone in maintaining the response.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|Clermont-Ferrand, France||CHU Estaing||no longer recruiting|
|Tours, France||CHU Bretonneau - Centre Henry Kaplan||no longer recruiting|
|Bordeaux, France||Institut Bergonié||no longer recruiting|
|Paris, France||Hôpital de la Pitié Salpétrière||no longer recruiting|
|Saint-Cloud, France||Institut curie - Hôpital René Huguenin||no longer recruiting|
|Grenoble, France||Chu Michallon||no longer recruiting|
|Nancy, France||Hôpital Central||no longer recruiting|
|Lille, France||CHRU Lille - Hôpital Claude Huriez||no longer recruiting|
|Lyon, France||Centre Léon Bérard||no longer recruiting|
|Rouen, France||Centre Henri Becquerel||no longer recruiting|
|Amiens, France||CHU Amiens -Hôpital Sud||no longer recruiting|
|Marseille, France||Chu La Timone||no longer recruiting|
|Endpoint classification||efficacy study|
|Intervention model||single group assignment|
Assess the efficacy of lenalidomide in combination with rituximab in relapsed/refractory PCNSL as measured by the objective response rate (CR + uCR + PR) at the end of the 8 cycles of induction therapy.
time frame: 33 months
The safety of the association during induction and maintenance therapy in a population of PCNSL (NCI V4)
time frame: 56 months
The duration of response
time frame: 56 months
Progressive Free Survival at one year from the date of inclusion to the date of progression of the disease or death
time frame: 56 months
Overall Survival from the date of inclusion to the date of death
time frame: 56 months
Quality of life using QLQ-C30 EORTC (European Organization for Research and Treatment of Cancer) questionnaire
time frame: 20 months
Male or female participants at least 18 years old.
Inclusion Criteria: 1. Patients over 18 years old with a refractory or relapse PCNSL and who have previously received at least high dose methotrexate (> 1.5 g/m²) and high dose cytarabine (2 g/m²). 2. Patients can have received radiotherapy or intensive chemotherapy with hematopoietic stem cell rescue as part of treatment of the PCNSL or IOL 3. Patients over 18 years old with a refractory or relapse IOL and who have received either intravenous high dose methotrexate (> 1.5 g/m2) or intraocular methotrexate 4. Life expectancy > 2 months 5. Able to swallow capsules (stomach tube not allowed) 6. Adequate bone marrow function with absolute leukocytes > 2000/mm3, neutrophil count (ANC) > 1000/mm3, haemoglobin > 8 g/dl and platelets > 100 000/mm3 7. Adequate liver function with Serum SGOT/AST or SGPT/ALT < 3.0 X Upper Limit of Normal ULN ; bilirubin < 1.5 X LNS (excepted in case of hemolytic anemia or Gilbert's syndrome) 8. Calculated creatinine clearance > 40 ml/min. Patients with calculated creatinine clearance between 40 and 50ml/min lenalidomide dose will be adjusted as follows (10mg once daily) 9. Patient aged 18 years old or more and without measure of legal protection 10. Able to understand teratogenic risks of the treatment 11. Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual contact during the following time periods related to this study for at least four weeks before starting study drug, while participating in the studyand for at least 4 weeks after discontinuation of Lenalidomide and 1 year after Rituximab.. Pregnancy tests (serum β-HCG dosage) will be negative at baseline and during the study. Men must agree not to procreate a child and use condoms if their partner can procreate, during all the treatment period, during dose interruptions and for at least 4 weeks after study drug discontinuation. 12. Signed inform consent Exclusion Criteria: 1. Contraindication to any drug contained in the chemotherapy regimen or to any of their excipients 2. T-cell lymphoma 3. Diagnosis of any second malignancy within the last 5 years 4. Prior history of organ transplantation or other cause of severe immunodeficiency 5. History of heart disease and/or impaired cardiac function (ECG QTc>450msec, congenital long QT syndrome, history of ventricular tachyarrhythmia, ventricular fibrillation, congestive heart failure NYHA III/IV, uncontrolled hypertension). 6. Known HIV or HTLV-1 infection, positive serology to HB surface antigen [HBsAg] or total HB core antibody [anti-HB-c]) and Hepatitis C (Hepatitis C virus [HCV] antibody) not older than 4 weeks 7. Inclusion in another experimental anti-cancer drug therapy* 8. Impossibility to follow the calendar of exams because of geographic, social or psychological reasons 9. Patient under measure of legal protection 10. No social security *For ethical reasons, the exclusion period within which the patient cannot be included in another trial will not be defined but discussed on a case to case basis.
|Official title||Phase II Study Evaluating the Efficacy of Lenalidomide in Association With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma (PCNSL)|
|Principal investigator||Carole SOUSSAIN, MD|
|Description||The investigators use a two-stage Fleming's design based on the following hypotheses under treatment: 10% (null hypothesis, minimal clinical benefit rate), 30% (alternative hypothesis, acceptable clinical benefit rate), 3% type I error rate, 5% type II error rate. Under these hypotheses, a total of 45 assessable patients will be necessary: 22 for the first stage + 23 for the second stage. Stage 1: following the inclusion of the first 22 assessable patients, if 0 or 1 patient has an objective response (CR, Complete Response + uCR, unconfirmed Complete Response + PR, Partial Response) at the end of induction treatment, the study would be terminated early and the treatment will be considered ineffective. If 2 or more patients have an objective response at the end of induction treatment, then the treatment will be considered as effective in this indication. Otherwise, the second group of 23 patients will be recruited. Stage 2: if at the end of recruitment, 8 or less patients have an objective response, the investigators will conclude to inefficacy, and if 9 or more patients have an objective response, then the treatment will be considered as effective and need further exploration.|
Call for more information